The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Fac...
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a paradigm shift in melanoma treatment, to surmount...
Alternative Titles
Full title
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e356ec7b9fdf481db44e3867ff78144c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e356ec7b9fdf481db44e3867ff78144c
Other Identifiers
ISSN
1476-4598
E-ISSN
1476-4598
DOI
10.1186/s12943-020-01290-7
